Bio-Path Holdings Appoints Mark Colonnese to its Board of Directors
July 17 2017 - 8:00AM
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company
leveraging its proprietary DNAbilize™ liposomal delivery and
antisense technology to develop a portfolio of targeted nucleic
acid cancer drugs, today announced the appointment of Mark
Colonnese, Chief Financial Officer of Aviragen Therapeutics
(NASDAQ:AVIR), to its Board of Directors.
“We are delighted to welcome Mark to our Board of Directors. His
wide-ranging experience in the biotech sector will be invaluable to
Bio-Path as we advance our DNAbilize therapies through the clinic,”
said Peter H. Nielsen, Chief Executive Officer of Bio-Path
Holdings. “In particular, Mark’s deep financial expertise will be a
great asset as we continue to grow Bio-Path into a leading
biopharmaceutical company.”
“It is exciting to join Bio-Path at this early stage of its
development in order to help maximize the potential of the
DNAbilize technology and its various therapeutic programs,” said
Mr. Colonnese. “I look forward to working with Bio-Path’s Board and
management to develop targeted DNA therapeutics in oncology and to
expand into other therapeutic areas.”
Mr. Colonnese brings over 30 years of broad executive management
skills and financial experience at Fortune 500 as well as small
entrepreneurial companies. He currently serves as the Executive
Vice President and Chief Financial Officer of Aviragen
Therapeutics, Inc., a NASDAQ-listed antiviral drug development
company. Earlier in his career, Mr. Colonnese was chief financial
officer at a number of biotechnology companies including Stealth
BioTherapeutics, Transgenomic Inc., and AtheroGenics Inc. Mr.
Colonnese also served as Vice President, Financial Operations at
Schering-Plough Corporation, now part of Merck, one of the world’s
largest pharmaceutical companies. In these roles, he was
responsible for raising $870 million in equity and debt capital, as
well as $100 million from partnerships, and directing two companies
through their initial public offerings. Mr. Colonnese holds a
Master of Business Administration from Fairleigh Dickinson
University and a Bachelor of Science, magna cum laude from Ithaca
College.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing
therapeutic products utilizing DNAbilize™, its proprietary
liposomal delivery and antisense technology, to systemically
distribute nucleic acid drugs throughout the human body with a
simple intravenous transfusion. Bio-Path’s lead product candidate,
prexigebersen (BP1001, liposomal Grb2 antisense), is in a Phase II
study for blood cancers and in preclinical studies for solid
tumors. Bio-Path’s second drug candidate, also a liposomal
antisense drug, is ready for the clinic where it will be evaluated
in lymphoma and solid tumors.
For more information, please visit the Company's website at
http://www.biopathholdings.com.
Contact Information:
Investors
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024